Studies With Apolipoprotein A-II Transgenic Mice Indicate a Role for HDLs in Adiposity and Insulin Resistance

  1. Lawrence W. Castellani1,
  2. Aimie M. Goto1 and
  3. Aldons J. Lusis123
  1. 1Medicine and
  2. 2Microbiology, Immunology and Molecular Genetics, and the
  3. 3Molecular Biology Institute, University of California, Los Angeles, California

    Abstract

    Apolipoprotein A-II (apoA-II) is the second most abundant protein in HDLs. Genetic studies in humans have provided evidence of linkage of the apoA-II gene locus to plasma free fatty acid (FFA) levels and to type 2 diabetes, and transgenic mice overexpressing mouse apoA-II have elevated levels of both FFA and triglycerides. We now show that apoA-II promotes insulin resistance and has diverse effects on fat homeostasis. ApoA-II transgenic mice have increased adipose mass and higher plasma leptin levels than C57BL/6J control mice. Fasting glucose levels were similar between apoA-II transgenic and control mice, but plasma insulin levels were elevated approximately twofold in the apoA-II transgenic mice. Compared with control mice, apoA-II transgenic mice exhibited a delay in plasma clearance of a glucose bolus. Adipose tissue isolated from fasted apoA-II transgenic mice exhibited a 50% decrease in triglyceride hydrolysis compared with adipose tissue from control mice. This is consistent with a normal response of adipose tissue to the increased insulin levels in the apoA-II transgenic mice and may partially explain the increased fat deposition. Skeletal muscle isolated from fasted apoA-II transgenic mice exhibited reduced uptake of 2-deoxyglucose compared with muscles isolated from control mice. Our observations indicate that a primary disturbance in lipoprotein metabolism can result in several traits associated with insulin resistance, consistent with the hypothesis that insulin resistance and type 2 diabetes can, under certain circumstances, be related primarily to altered lipid metabolism rather than glucose metabolism.

    Footnotes

    • Address correspondence and reprint requests to Lawrence W. Castellani, Department of Medicine/Division of Cardiology, 47-123 CHS, University of California, Los Angeles, CA 90095. E-mail: lcastellani{at}mednet.ucla.edu.

      Received for publication 25 April 2000 and accepted in revised form 27 November 2000.

    « Previous | Next Article »Table of Contents